Cargando…
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for various types of cancer. For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promis...
Autor principal: | Hosen, Naoki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966463/ https://www.ncbi.nlm.nih.gov/pubmed/31847470 http://dx.doi.org/10.3390/cancers11122024 |
Ejemplares similares
-
Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019) -
Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019) -
Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022) -
Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020) -
Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
por: Padda, Jaskamal, et al.
Publicado: (2021)